Goldman Sachs
GALT icon

Goldman Sachs’s Galectin Therapeutics GALT Stock Holding History

Goldman Sachs’s Portfolio GALT Stock Details GALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-4,800
Closed -$7K – 7098
2016
Q1 		$7K Buy
+4,800
New +$6.44K ﹤0.01% 6945
2015
Q3 		– Sell
-2,100
Closed -$6K – 7354
2015
Q2 		$6K Sell
2,100
-800
-28% -$2.41K ﹤0.01% 7184
2015
Q1 		$10K Sell
2,900
-4,200
-59% -$15K ﹤0.01% 6974
2014
Q4 		$25K Sell
7,100
-1,900
-21% -$8.4K ﹤0.01% 6955
2014
Q3 		$45K Sell
9,000
-800
-8% -$6.23K ﹤0.01% 6848
2014
Q2 		$135K Sell
9,800
-300
-3% -$3.73K ﹤0.01% 6434
2014
Q1 		$155K Buy
+10,100
New +$144K ﹤0.01% 6222

Other funds holding GALT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WANY
Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Goldman Sachs's GALT Position: Q2 2026 in Review

Goldman Sachs reduced its Galectin Therapeutics (GALT) stake by 60% in Q2 2026, selling an estimated $286K and leaving 74,554 shares worth $346K. The position accounts for ﹤0.01% of the portfolio, ranked #5934.

Goldman Sachs first reported a position in GALT in Q1 2014 and has held it in 40 quarters since. The position peaked at $1.28M in Q4 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

  • Goldman Sachs held 74,554 shares of Galectin Therapeutics worth $346K as of Q2 2026.
  • Goldman Sachs sold 110,183 Galectin Therapeutics shares in Q2 2026, an estimated $286K.
  • Galectin Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q2 2026, its #5934 holding.
  • Goldman Sachs first reported a position in Galectin Therapeutics in Q1 2014 and has held it in 40 quarters since.
  • Goldman Sachs's Galectin Therapeutics position peaked at $1.28M in Q4 2025.
  • 98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.